Telix Pharmaceuticals reported unaudited group revenue of $204 million for Q2 2025, a 63% increase year-over-year. The company reaffirmed its FY 2025 revenue guidance of $770-800 million. Gozellix® launched in the U.S. with a Level II HCPCS code, and the ProstACT™ Global Phase 3 trial expanded globally.

Telix’s therapeutics business saw progress with its prostate cancer therapy candidates, including TLX591 and TLX592. The company has obtained regulatory approvals to expand trials into China, Japan, and Canada. Telix also submitted applications for clinical trials of TLX101 and TLX250 for various cancers.

In precision medicine, Telix received approvals for Illuccix in several European countries and completed enrollment for a Phase 3 study in China. The company also submitted applications for clinical trials aimed at expanding the label indication for Illuccix and Gozellix. Telix announced a new PET radiochemistry solution and signed an agreement for a novel targeting agent.

Telix Manufacturing Solutions (TMS) announced the opening of a GMP manufacturing facility in Yokohama, Japan, and produced its first GMP commercial radiopharmaceutical doses in Belgium. Additionally, Telix received a subpoena from the U.S. but did not provide further details. The Securities and Exchange Commission (SEC) has requested documents from Telix Pharmaceuticals related to disclosures about the development of its prostate cancer therapeutic candidates. Telix is cooperating with the SEC, and the inquiry is currently in the fact-finding stage.

Telix confirms its revenue guidance for FY 2025, expecting $770 million to $800 million. The guidance includes revenue from Illuccix sales and increased R&D investment compared to the previous year.

The SEC’s information request does not imply any violations of securities laws or negative opinions. Telix will continue its clinical development programs for prostate cancer therapy candidates while the inquiry is ongoing. The request does not affect Telix’s commercial and late-stage precision medicine products.

Telix Pharmaceuticals is a biopharmaceutical company focusing on therapeutic and diagnostic radiopharmaceuticals. It has a global presence and is listed on the ASX and Nasdaq. The company’s products include prostate imaging agents and an osteomyelitis imaging agent approved in various markets.

Investors should be cautious about Telix’s revenue guidance due to potential risks and uncertainties. Factors like R&D success, regulatory decisions, competition, and market conditions could affect actual results. Telix disclaims any obligation to update forward-looking statements and financial forecasts. Telix Pharmaceuticals Limited has announced significant milestones in their business operations, including the initiation of preclinical and clinical trials, regulatory approvals for their product candidates in various countries, and advancements in research and development programs. These achievements mark important progress for Telix in the healthcare industry.

The company’s revenue growth has been substantial, with key contributions from sales of Illuccix and revenue generated from the acquisition of Radiopharmaceutical Logistics Solutions. These financial results demonstrate Telix’s success in commercializing their product candidates and expanding their market presence.

Telix Pharmaceuticals Limited has made strategic moves to secure trademark rights for their products, emphasizing their commitment to brand recognition and protection. This effort reflects the company’s dedication to establishing a strong presence in the pharmaceutical industry and ensuring the credibility of their products in the market.

As Telix Pharmaceuticals Limited continues to advance their product candidates and expand their market reach, they aim to drive further growth and innovation in the healthcare sector. With a focus on research, development, and commercialization, Telix is positioned to make significant contributions to improving patient outcomes and advancing medical technology.

Read more at GlobeNewswire: Telix Reports $204M Revenue, Up 63% YOY